Autoimmune hepatitis

Current Treatment Options in Gastroenterology

Volumn 8, Issue 6, 2005, Pages 481-492

  Ahn, Joseph ^b   Flamm, Steven L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTHIOINOSINE; ACICLOVIR; ALLOPURINOL; ALUMINUM HYDROXIDE; ANTACID AGENT; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLESTYRAMINE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUCONAZOLE; GANCICLOVIR; HISTAMINE H2 RECEPTOR ANTAGONIST; MAGNESIUM HYDROXIDE; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PREDNISOLONE; PREDNISONE; PROBENECID; PROTON PUMP INHIBITOR; RIFAMPICIN; TACROLIMUS; THIOGUANOSINE; UNINDEXED DRUG; VITAMIN D; WARFARIN;

ACNE; ADRENAL INSUFFICIENCY; ALOPECIA; ARTHRALGIA; AUTOIMMUNE HEPATITIS; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; BUFFALO HUMP; CANCER; CARDIOVASCULAR DISEASE; CATARACT; CENTRAL PONTINE MYELINOLYSIS; CHEMICAL PARAMETERS; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DEPRESSION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EMOTIONAL DISORDER; EUPHORIA; EXERCISE; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLAUCOMA; GLUCOSE INTOLERANCE; HEALING IMPAIRMENT; HIP DISEASE; HIRSUTISM; HISTOLOGY; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; IRRITABILITY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; LONG TERM CARE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALAISE; MEDICAL SOCIETY; MOON FACE; MYOPATHY; NAUSEA AND VOMITING; NEOPLASM; NEUROTOXICITY; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PNEUMONIA; RELAPSE; REMISSION; REVIEW; RIGOR; SAMPLE SIZE; SCORING SYSTEM; SEIZURE; SIDE EFFECT; STRIA; TACHYCARDIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TREMOR;

EID: 30344459998     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0035-7     Document Type: Review

References (44)

1. Johnson PJ, McFarlane IG: Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
2. Ludwig J, McFarlane IG, Rakela J: International Working Party Report: Terminology of chronic hepatitis. Am J Gastro 1995, 90:181-189.
3. Czaja AJ, Freese DK: AASLD Practice Guidelines-Diagnosis and treatment of autoimmune hepatitis. Hepatology, 2002, 36:479-497.
4. Medina J, Garcia-Buey L, Moreno-Otero R: Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment Pharmacol Ther, 2003, 17:1-16.
5. Boberg KM, Aadland E, Jahnsen J, et al.: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastro 1998, 33:99-103.
6. Nishioka M, Morshed SA, McFarlane IG: Geographical variation in the frequency and characteristics of autoimmune liver disease, in Autoimmune liver diseases, W.R. Krawitt EL, Nishioka M, Editor. Elsevier: Amsterdam. 1998, 413-424.
7. Lim KN, Casanova RL, Boyer TD, et al.: Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastro 2001, 96:3390-3394.
8. Schalm SW, Korman MG, Summerskill WH, et al.: Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977, 22:973-980.
9. Czaja AJ, Davis GL, Ludwig J, et al.: Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983, 85:713-717.
10. Czaja AJ, Davis GL, Ludwig J, Taswell HF: Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984, 4:622-627.
11. Alvarez F, Berg PA, Bianchi FB, et al.: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
12. Roberts SK, Therneau T, Czaja AJ: Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996, 110:848-857.
13. Seaberg EC, Belle SH, Beringer KC, et al.: Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS liver transplant registry. In Clinical Transplants 1998. Edited by Cecka JM. Los Angeles: UCLA Tissue Typing Laboratories; 1999:17-37.
14. Czaja AJ, Francesco BB, Carpenter HA, et al.: Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005, 41:207-215.
15. Czaja AJ, Wolf AM, Baggenstoss AH: Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981, 80:687-692.
16. Soloway RD, Summerskill WHJ, Baggenstoss AH, et al.: Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972, 63:820-833.
17. Schalm SW, Ammon HV, Summerskill WH: Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976, 8:221-227.
18. Czaja AJ, Menon KV, Carpenter HA: Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002, 35:890-897.
19. Hayash M, Keeffe EB, Krams SM, et al.: Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg 1998, 4:208-214.
20. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001, 44:1496-1503.
21. Czaja AJ: Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990, 11:1044-1049.
22. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH: Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975, 16:876-883.
23. Connell WR: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343:1249-1252.
24. Devlin J, Donaldson P, Portmann B: Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl Surg 1995, 1:162-165.
25. Gotz G, Neuhaus R, Bechstein WO, et al.: Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc 1999, 31:430-431.
26. Milkiewicz P, Hubscher SG, Skiba G, et al.: Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999, 68:253-256.
27. Ratziu V, Samuel D, Sebagh M, et al.: Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999, 30:131-141.
28. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al.: Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001, 7:302-310.
29. Richardson PD, James PD, Ryder SD: Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000, 33:371-375.
30. Devlin SM, Swain MG, Urbanski SJ, Burak KW: Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol, 2004, 18:321-326.
31. Fernandes NF, Redeker AG, Vierling JM, et al.: Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastro 1999, 94:241-248.
32. Van Thiel DH, Wright H, Carroll P, et al.: Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastro 1995, 90:771-776.
33. Aqel BA, Machicao V, Rosser B, et al.: Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004, 38:805-809.
34. Heneghan MA, Rizzi P, McFarlane IG, et al.: Low dose tacrolimus as treatment of severe autoimmune hepatitis: potential role in remission induction. Gut 1999, 44:A61.
35. Danielsson A, Prytz H: Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994, 8:585-590.
36. Czaja AJ, Lindor KD: Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000, 119:1312-1316.
37. Nakamura K, Yoneda M, Yokohama S, et al.: Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998, 13:490-495.
38. Czaja AJ, Carpenter HA, Lindor KD: Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999, 30:1381-1386.
39. Pratt DS, Flavin DP, Kaplan MM: The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996, 110:271-274.
40. Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, et al.: Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis. Rev Esp Enferm Dig 1999, 91:630-638.
41. Burak KW, Urbanski SJ, Swain MG: Successful treatment of refractory type I autoimmune hepatitis with methotrexate. J Hepatol 1998, 29:990-993.
42. Venkataramani A, Jones MB, Sorrell MF: Methotrexate therapy for refractory chronic active autoimmune hepatitis. Am J Gastro 2001, 96:3432-3433.
43. Kanzler S, Gerken G, Dienes HP, et al.: Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis- report of three cases. Z Gastroenterol 1997, 35:571-578.
44. Kerkar N, Dugan C, Rumbo C, et al.: Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplantation 2005, 5:1085-1089.